Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Metrics to compare | NNNN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNNNNPeersSector | |
---|---|---|---|---|
P/E Ratio | 791.7x | −0.2x | −0.5x | |
PEG Ratio | −16.98 | −0.19 | 0.00 | |
Price/Book | 109.3x | 3.2x | 2.6x | |
Price / LTM Sales | 229.5x | 10.0x | 3.3x | |
Upside (Analyst Target) | - | 169.6% | 45.4% | |
Fair Value Upside | Unlock | 7.0% | 7.7% | Unlock |